National Bank of Canada
JSPR icon

National Bank of Canada’s Jasper Therapeutics JSPR Stock Holding History

National Bank of Canada’s Portfolio JSPR Stock Details JSPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$139 Hold
160
– – ﹤0.01% 2817
2025
Q4 		$291 Buy
160
+80
+100% +$161 ﹤0.01% 2727
2025
Q3 		$190 Hold
80
– – ﹤0.01% 2745
2025
Q2 		$444 Buy
80
+40
+100% +$197 ﹤0.01% 2774
2025
Q1 		$172 Buy
+40
New +$266 ﹤0.01% 2696
2024
Q4 		– Sell
-1
Closed -$19 – 3071
2024
Q3 		$19 Sell
1
-99
-99% -$1.97K ﹤0.01% 2649
2024
Q2 		$2.31K Hold
100
– – ﹤0.01% 2406
2024
Q1 		$2.12K Buy
+100
New +$1.78K ﹤0.01% 2442

Other funds holding JSPR

VCIM
Velan Capital Investment Management Alpharetta, Georgia $160M AUM 517.12% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $352M AUM 299.18% 1-Year Est. Return
KCM
Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
CG
Carlyle Group Washington, District of Columbia $10.6B AUM 11.25% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return
LPC
Lion Point Capital New York $16.7M AUM 119.35% 1-Year Est. Return

National Bank of Canada's JSPR Position: Q1 2026 in Review

National Bank of Canada held its Jasper Therapeutics (JSPR) position steady in Q1 2026 at 160 shares worth $139. The position accounts for ﹤0.01% of the portfolio, ranked #2817.

National Bank of Canada first reported a position in JSPR in Q1 2024 and has held it in 8 quarters since. The position peaked at $2.31K in Q2 2024. 58 funds tracked by Wall St. Rank hold JSPR as of Q1 2026.

  • National Bank of Canada held 160 shares of Jasper Therapeutics worth $139 as of Q1 2026.
  • National Bank of Canada left its Jasper Therapeutics share count unchanged in Q1 2026.
  • Jasper Therapeutics made up ﹤0.01% of National Bank of Canada's portfolio in Q1 2026, its #2817 holding.
  • National Bank of Canada first reported a position in Jasper Therapeutics in Q1 2024 and has held it in 8 quarters since.
  • National Bank of Canada's Jasper Therapeutics position peaked at $2.31K in Q2 2024.
  • 58 funds tracked by Wall St. Rank held Jasper Therapeutics as of Q1 2026.

Based on National Bank of Canada's 13F filing for Q1 2026, filed 15 May 2026.